Tags: biotechpatientpharmaPolicy & Regulationpolicy-regulation
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey | ||
| 2 | Meagan Parrish Pharma Voice Senior editor @industrydive.
Pharma world follower. Wisconsin, USA | The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - 5 days ago After Amylyx drug failure, what’s next for ALS? - 8 months ago ‘1 plus 1 equals 3’ — the co-CEO model in pharma - 10 months ago | |
| 3 | Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA | Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - about 1 month ago | |
| 4 | Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia | ||
| 5 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | Andrew Caldwell - 8 months ago | |
| 6 | Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland | ||
| 7 | Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. | ||
| 8 | Natasha Lomas TechCrunch Journalist. Climber-in-training. Owns cats. Barcelona and London | ||
| 9 | Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts | STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 3 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 9 months ago | |
| 10 | Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. | STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 3 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - about 1 year ago |